Certis Oncology Solutions is a life science technology company with a mission to realize the promise of precision oncology. Our product is Oncology Intelligence™— highly predictive therapeutic response data derived from proprietary biological models of cancer. We apply these models to machine learning and AI-enhanced predictive algorithms, the development of the next generation of targeted cancer therapeutics, and functional precision medicine.

Established in 2016, Certis began its journey in functional precision oncology, helping cancer patients and their oncologists through YourPDX™ testing.

ACCELERATING THE DEVELOPMENT OF NEW CANCER THERAPIES
Certis partners with therapeutic developers to help close the problematic translational gap between preclinical studies and clinical trials. Through clinically relevant, well-characterized and annotated cancer models, advanced imaging technology, including x-ray irradiation with image-guided radiation therapy, and thoughtfully designed custom studies, our proprietary platform can bring greater certainty to go/no-go drug development decisions.

We are committed to providing translationally relevant preclinical models to drug developers for efficient and effective transition into the clinic.  Learn more about our preclinical oncology services.

Certis Oncology Solutions, Inc.

Certis Oncology announces closing of $10 million Series C fundraising round and names John R. Tozzi as new board chairman. Read the full press release now: https://hubs.la/Q02gPk9h0. #SeriesC #Fundraising #NewBoardMember #CancerResearch #LifesSciences #FightCancerTogether

Did you miss our recent talk on animal welfare in the preclinical CRO space? Register now to watch the full webinar recording hosted by Inside Scientific: https://hubs.la/Q02jc1Jc0. #CancerResearch #3Rs #AnimalWelfare #MouseModels #CancerModels #TranslationalResearch #FightCancer #CertaintySavesLives 

Stop by a Live Certis Poster Session Today at the 8th Annual Tumor Models San Francisco Summit! 
The Certis Team will present “In Vivo Tumor Implantation Site Exhibits Differential Immune Response in Solid Tumors” on Wednesday, January 31, at 4:50pm (PST). This upcoming poster presentation demonstrates differences in the tumor microenvironment, overall immune response, and the pharmacological outcome, between subcutaneous and orthotopic humanized PDX models using peripheral blood mononuclear cells. This sample figure shows a pathway enrichment analysis of top differentially expressed genes between subcutaneous and orthotopic tissue of PDX models that may functionally contribute to differences in therapy response.  

Find Your Model Match at the Certis Exhibitor Booth
Talk to us about your unique cancer model needs at the upcoming Tumor Models SF Summit! Finding the right preclinical models to evaluate efficacy and understand the complex mechanisms of action induced by your targeting compound(s) can be challenging. A strategic translational approach – combining the predictive power of artificial intelligence with advanced PDX and PDX-derived models – can accelerate your preclinical program. The cancer model database includes 56 unique PDX models and companion PDX-derived 3D cell cultures with the most common RAS mutations in cancer, including lung, colorectal, and pancreatic. Download the data pack now: https://hubs.la/Q02gjHBm0. #TMSF24 #TumorModels #WestCoastBioPharma #TranslationGap #CancerResearch #FightCancer #RareCancers #MetastaticCancers #CertaintySavesLives #CancerArtificialIntelligence #AI #IO #DrugDevelopment #DrugDiscovery  

HSTS

Amazon

LetsEncrypt

nginx

Cloudflare CDN

Person Schema

CrUX Dataset

Cloudflare Network Error Logging

CrUX Top 10m

Cloudflare Bot Manager

Chief Scientific Officer

Jonathan Nakashima

Marketing and Product

Kristein King

Peter Ellman

Director of Regulatory and Quality

Diana Hornberger

Director, Study Operations

Fernando Eguiarte-Solomon

Sales and Support

Howard Kartstein

Director of Bioinformatics and Data Science

Long Do

Sr. Director, Sales and Marketing Operations

Matthew Lee

Senior Director, Immuno-Oncology R&D

Rajeev Shrimali

Business Management

Sanghee Lee

Scott Arnold

Executive Vice President and Chief Financial Officer

CEO and Founder

Greater San Diego Area Companies With More Than 10 Employees (Top 10K)

Biotechnology Companies With More Than 10 Employees (Top 10K)

California Companies (Top 10K)

United States Late Stage Companies With Less Than $500M in Revenue

Certis is a precision oncology and translational science company.  Our product is Oncology Intelligence®—highly predictive therapeutic response data derived from advanced models of cancer. Certis partners with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using CertisAI™, our proprietary artificial intelligence/machine learning platform, and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy. Certis is ALAAAC-accredited and CLIA-certified for high-complexity testing.

Incite Ventures

Series C - Certis Oncology Solutions

Series A - Certis Oncology Solutions

Computer and Software Services and Scientific Services

San Diego

California

United States

North America

Certis Oncology Solutions

Certis Oncology Solutions, Inc. on LinkedIn: #headandneckcancers #tumormodels #cancermodels ...

Certis Oncology Solutions, Inc. on LinkedIn: #aacr24 #aiforgood #cancerresearch #precisiononcology #fightcancer

Certis Oncology Solutions, Inc. on LinkedIn: #functionalprecisiononcology #personalizedcancermedicine…

Certis Maps ‘Clear Path to Profitable Growth’

Certis Oncology Announces Closing of $10 Million Series C Fundraising Round

A platform providing predictive therapeutic response data derived from advanced cancer models and enhanced with AI-driven bioinformatics.

A database offering access to highly characterized cancer models for preclinical studies, with features for detailed queries and model selection.

An AI-driven platform that predicts individual drug responses using gene expression biomarkers and multivariate analyses.

Cancer models created by implanting human tumor tissue in the corresponding anatomical location in mice, used for evaluating cancer therapies.

3D cell cultures derived from PDX models that more accurately represent cancer complexities compared to traditional 2D cultures.

Custom assays and cell line development services for early screening and hypothesis generation in preclinical studies.

The Netherlands

Europe

Spain

India

Asia

Pakistan

Nanoligent is a competitor of Certis Oncology Solutions specializing in advanced molecular and immune profiling services for oncology. They offer comprehensive genomic profiling to guide treatment decisions.

Nanoligent

Rincon Bio is a competitor of Certis Oncology Solutions, providing advanced molecular and immune profiling services for oncology. They focus on comprehensive genomic profiling to support precision medicine in cancer treatment.

Rincon Bio

Xentech is a competitor of Certis Oncology Solutions, specializing in advanced molecular and immune profiling services for oncology. They aim to provide comprehensive genomic profiling to assist in treatment decisions for cancer patients.

Xentech

Certis Oncology Solutions is a company that specializes in providing advanced molecular and immune profiling services for oncology. Their services are aimed at supporting precision medicine in cancer treatment, offering comprehensive genomic profiling to help guide treatment decisions.

news impact assignment basic	general
public peers	general	May 12, 2024 12:51 PM	312928ad
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 12, 2024 6:40 PM	9b7790cd
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	738caf08
crunchbase profile	general	Nov 19, 2024 1:38 AM	b9c594f6
li profile	general	May 12, 2024 12:51 PM	5c55eea4
translate crunchbase fundingrounds	general	Nov 19, 2024 2:02 AM	1bf707c7
peers	general
news basic	general	May 12, 2024 12:51 PM	2168adee
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CERTISONCOLOGY

Certis Oncology Solutions